WuXi AppTec (603259.SH) subsidiary plans to subscribe for 10 million euros worth of investment fund shares.

WuXi AppTec (603259.SH) announced that on November 15, 2024, its wholly-owned subsidiary WuXi PharmaTech Healthcare Fund I L.P. (referred to as "WuXi Fund I") signed a Subscription Agreement with Sofinnova Capital XI GP S. r.l. (referred to as the "General Partner"), agreeing to subscribe for 10 million euros of fund units in Sofinnova Capital XI SCSp SICAV-RAIF (referred to as the "Investment Fund"), representing approximately 4.40% of the total fund units raised (the proportion of fund units held by WuXi Fund I will be further diluted as additional funds are raised by the Investment Fund). As of the date of this announcement, WuXi Fund I has not yet paid the investment amount, and will use its own funds to fulfill the payment obligation as required by the Subscription Agreement in the future. The Investment Fund, established under the laws of the Grand Duchy of Luxembourg, focuses on investing in start-up companies in the life sciences sector worldwide, particularly in the biopharmaceutical and medical device industries.